3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Neoplasms
14
Venous Thromboembolism
11
Venous Thrombosis
4
Thrombosis
3
Pulmonary Embolism
3
Multiple Myeloma
3
Upper Extremity Deep Vein Thrombosis
2
Lung Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thromboembolism
1
Stomach Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Prevention of Venous Thromboembolism
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Myeloproliferative Disorders
1
Lymphoma
1
Leukemia
1
Inflammation
1
Immune System Diseases
1
Hemorrhage
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Interventions
Cyclophosphamide
8
fludarabine phosphate
6
fludarabine
5
Bendamustine Hydrochloride
4
Busulfan
3
AP 1903 reagent
3
pembrolizumab
2
Tacrolimus
2
Mycophenolic Acid
2
thymoglobulin
1
pimonidazole
1
palbociclib
1
ibritumomab tiuxetan
1
Valsartan
1
Telemedicine
1
Surveys and Questionnaires
1
Rivaroxaban
1
Rituximab
1
Radiotherapy
1
Plasmalyte A
1
Pharmacogenomic Testing
1
Melphalan
1
Hydroxychloroquine
1
Etoposide
1
Dimethyl Sulfoxide
1
Cytarabine
1
Carmustine
1
Bone Marrow Transplantation
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Immune System Diseases
×
Rivaroxaban
×
Clear all
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled